Hepatitis B virus (HBV) is a globally prevalent pathogen responsible for both acute and chronic liver disease. In pediatric populations, HBV poses unique challenges due to its high rate of perinatal transmission, potential for silent chronic infection, and long-term risk of hepatocellular carcinoma (HCC). Understanding the virology, transmission dynamics, clinical manifestations, and management strategies is essential for pediatricians, hepatologists, and public health professionals.
HBV is a partially double-stranded DNA virus belonging to the Hepadnaviridae family. The virus consists of:
A nucleocapsid core containing the hepatitis B core antigen (HBcAg), viral DNA, and hepatitis B envelope antigen (HBeAg)
An outer lipoprotein envelope embedded with hepatitis B surface antigen (HBsAg)
The presence of HBsAg in serum indicates active infection, while HBeAg reflects active viral replication and high infectivity. HBV replicates via reverse transcription, a unique feature among DNA viruses, and integrates into host hepatocyte DNA, contributing to its persistence and oncogenic potential.
HBV affects over 250 million people worldwide, with significant geographic variation in prevalence. Eight genotypes (A–H) have been identified, each with distinct geographic distributions and clinical implications. Genotype C, for example, is more commonly associated with cirrhosis and an increased risk of HCC. Genotype also influences the likelihood of spontaneous seroconversion and response to antiviral therapy.
In children, the risk of developing chronic HBV infection is inversely related to age at acquisition:
Infants: ~90% risk of chronic infection
Children aged 1–5 years: 25–50%
Children >5 years: 5–10%
This age-dependent risk underscores the importance of early immunization and perinatal prophylaxis.
HBV is transmitted through exposure to infected blood and bodily fluids. In pediatric populations, the most common routes include:
Vertical transmission: From mother to infant during childbirth. Risk is highest when the mother is HBeAg-positive, with transmission rates ranging from 20% to 90%.
Parenteral and percutaneous exposure: Through contaminated needles, transfusions, or medical procedures.
Sexual transmission: Relevant in adolescents.
Horizontal transmission: Among children in endemic areas via close contact or shared personal items.
Perinatal transmission is particularly concerning because infants often remain asymptomatic yet develop chronic infection with long-term complications.
HBV is not directly cytopathic. Liver injury results from the host’s immune response to infected hepatocytes. Cytotoxic T lymphocytes recognize HBV antigens and mediate hepatocyte destruction, leading to inflammation and fibrosis. The strength and nature of the immune response determine whether the infection resolves or progresses to chronicity.
Children with acute HBV infection may present with:
Anorexia, nausea, and vomiting
Fever and fatigue
Jaundice and dark urine
Abdominal pain
An “arthritis-dermatitis” prodrome (especially in older children and adolescents)
However, many pediatric cases are asymptomatic or mild. Fulminant hepatitis is rare but can occur, particularly in neonates born to HBeAg-positive mothers.
Most children with chronic HBV are asymptomatic. The infection may remain in an immune-tolerant phase for years, characterized by high viral replication but minimal liver inflammation. Over time, some children transition to immune-active phases, with elevated transaminases and progressive liver damage.
HBV is associated with extrahepatic manifestations, including:
Polyarteritis nodosa: A necrotizing vasculitis
Membranous glomerulonephritis: Immune complex-mediated kidney disease
Diagnosis relies on serologic and molecular markers:
HBsAg: Indicates current infection (acute or chronic)
Anti-HBc IgM: Marker of acute infection
Anti-HBc IgG: Indicates past or chronic infection
HBeAg: Reflects active viral replication and high infectivity
Anti-HBe: Indicates seroconversion and lower infectivity
Anti-HBs: Marker of immunity (from vaccination or resolved infection)
HBV DNA: Quantifies viral load and guides treatment decisions
| HBsAg | Anti-HBc | Anti-HBs | Interpretation |
|---|---|---|---|
| Negative | Positive | Positive | Immune due to previous infection |
| Negative | Negative | Positive | Immune due to vaccination |
| Positive | Negative | Negative | Acutely infected |
| Positive | Positive (IgM) | Negative | Chronically infected |
| Negative | Positive | Negative | Resolved or low-level chronic infection |
Chronic HBV infection is defined by persistence of HBsAg for more than six months. The natural history includes several phases:
Immune-tolerant phase: High HBV DNA, normal ALT, minimal inflammation
Immune-active phase: Elevated ALT, active inflammation, risk of fibrosis
Inactive carrier state: HBeAg-negative, low HBV DNA, normal ALT
Reactivation phase: Fluctuating HBV DNA and ALT, risk of progression
Approximately 20% of carriers may experience flare-ups, reverting to HBeAg-positive immune-active hepatitis. These episodes are marked by increased HBV DNA and transaminase levels.
Children with chronic HBV require routine monitoring of:
ALT and AST
HBV DNA levels
HBeAg and anti-HBe status
α-fetoprotein (AFP) for HCC surveillance
Liver biopsy in chronic HBV may reveal the classic “ground glass” appearance of hepatocytes, reflecting accumulation of viral surface antigen within the cytoplasm. Biopsy also helps assess inflammation and fibrosis, guiding treatment decisions.
Treatment is indicated for children with evidence of active liver disease, typically defined as:
ALT >1.5× upper limit of normal (ULN) for ≥6 months (HBeAg-positive) or ≥12 months (HBeAg-negative)
HBV DNA >20,000 IU/mL
Recommended for children >12 months
Contraindicated in cirrhosis or decompensated liver disease
Treatment duration: ≥6–12 months
Predictors of response: ALT >2× ULN, low HBV DNA, active inflammation, female sex, younger age
Adverse effects: flu-like symptoms, bone marrow suppression, growth delay, depression, thyroid dysfunction
These oral agents suppress viral replication:
Lamivudine
Adefovir
Entecavir
Telbivudine
Tenofovir
Resistance and mitochondrial toxicity (e.g., lactic acidosis) are concerns. Genotypic resistance testing is advised if treatment failure is suspected.
Undetectable HBV DNA
Seroconversion to anti-HBe (loss of HBeAg)
Normalization of ALT
Histologic improvement
Universal HBV vaccination is recommended for all infants, typically administered as a three-dose series starting at birth. Additional indications include:
Household contacts of HBV-infected individuals
Children with chronic liver disease
International travelers to endemic areas
Infants born to HBsAg-positive mothers should receive:
Hepatitis B immune globulin (HBIG) within 12 hours of birth
HBV vaccine series starting at birth
Unvaccinated individuals exposed to HBV should receive HBIG and begin vaccination promptly.
Standard precautions include:
Avoiding shared personal items (razors, toothbrushes)
Safe handling of blood and body fluids
Screening blood products
Chronic HBV infection increases the risk of HCC, even in children. Annual screening with AFP and hepatic ultrasound is recommended for high-risk patients, including those with cirrhosis or family history of HCC.
Children with end-stage liver disease due to HBV may require transplantation. However, HBV recurrence in the graft is common and can lead to severe disease. Post-transplant prophylaxis with antiviral agents and HBIG is essential to reduce recurrence risk.
Pregnant women with HBV can transmit the virus to their infants, especially if they are HBeAg-positive. Transmission risk ranges from 20% to 90%, depending on maternal viral load and antigen status. To prevent neonatal infection:
Screen all pregnant women for HBsAg
Administer HBIG and HBV vaccine to exposed infants within 12 hours of birth
Consider antiviral therapy during pregnancy for mothers with high HBV DNA levels
Hepatitis B remains a significant cause of pediatric liver disease worldwide. Its unique virology, age-dependent risk of chronicity, and long-term complications necessitate early identification, vigilant monitoring, and timely intervention. Universal vaccination, perinatal prophylaxis, and targeted